TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06383273
Drug: Midalozam sublingual tablet
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each dose of midazolam will be provided as a single sublingual tablet, containing 3 mg midazolam. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
Study: NCT05789030
Drug: Diprospan plus iguratimod
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Patients are treated with Diprospan (1mL im) and then with iguratimod (25mg bid) for 12 months.
Study: NCT05789030
Drug: Diprospan plus leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated with Diprospan (1mL im) and then with leflunomide (10-20mg qd) for 12 months.
Study: NCT05789030
Drug: Prednisone plus leflunomide
Normalized name: Leflunomide
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated with prednisone (20 mg qd and taper to ≦ 5mg in 3 months) and leflunomide (10-20mg qd) for 12 months.
Study: NCT03593252
Drug: Senna
Normalized name: Senna
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative,used for bowel preparation
Study: NCT03593252
Drug: Metronidazole Oral
Normalized name: metronidazole Oral Gel
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral antibiotic
Study: NCT03593252
Drug: Neomycin
Normalized name: Neomycin
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral non-absorbable antibiotic
Study: NCT03593252
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
Study: NCT03593252
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
Study: NCT05590286
Drug: Vonoprazan Tablets
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan 20 mg, tablets, orally，QD
Study: NCT05590286
Drug: Amoxicillin Capsules
Normalized name: Amoxicillin Capsules
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 750mg, Capsules ,orally，QID
Study: NCT05590286
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 20mg, Capsules ,orally，BID
Study: NCT05735431
Drug: Administration of investigation drug
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
Study: NCT05735431
Drug: Administration of comparator
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
Study: NCT06413186
Drug: Uteratonic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer IV 10 IU oxytocin
Study: NCT05376228
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As part of standard of care
Study: NCT06534450
Drug: IVIG
Normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Immunoglobulin
Study: NCT05640778
Drug: Dalpiciclib combined with aromatase inhibitors
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib combined with letrozole or anastrozole
Study: NCT05171049
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg followed by 5 mg
Study: NCT04002011
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of \[2.0-3.0\]. Other anticoagulants will be not administrated.
Study: NCT04002011
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
Study: NCT06371807
Drug: Pembrolizumab injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: (KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting
Study: NCT05567796
Drug: Cagrilintide
Normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide will be administered subcutaneously.
Study: NCT05567796
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will recieve semaglutide subcutaneously.
Study: NCT04002011
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
Study: NCT04002011
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
Study: NCT04002011
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
Study: NCT06223932
Drug: Molnupiravir
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
Study: NCT00086203
Drug: Talabostat mesylate (PT-100) tablets
Normalized name: delavirdine
DrugBank: Talabostat (DB06182)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00086203
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02239276
Drug: Stiripentol
Normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The initial dose of Stiripentol will be determined by the prescribing neurologist and titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day. Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg total daily dose may be necessary for improved seizure control.
Study: NCT05048017
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib, 120 mg, once a day, 3 weeks on/1 week off
Study: NCT05048017
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab: 200mg (BW ≥ 50 kg) or 3 mg/kg (BW \< 50 kg) Toripalimab: 240mg is given through intravenous drip every 3 weeks on Day 1 of each course of treatment.~Pembrolizumab: 200mg is given through intravenous drip every 3 weeks.
Study: NCT05571787
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26
Study: NCT06229795
Drug: Green Tea Leaf Extract Decaffeinated
Normalized name: green tea leaf extract decaffeinated
DrugBank: Tea leaf (DB10580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg film coated tablet
Study: NCT06229795
Drug: Metformin Hydrochloride 500 MG
Normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg tablet
Study: NCT01523379
Drug: Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 90mg Parecoxib i.v. two times a day, two days in a row
Study: NCT05572281
Drug: Tasimelteon Oral Capsule
Normalized name: tasimelteon Oral Capsule
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No additional information
Study: NCT05572281
Drug: Tasimelteon Oral Suspension
Normalized name: tasimelteon Oral Suspension
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No additional information
Study: NCT05754840
Drug: MPL-001
Normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD. The MPL-001 oil is produced by MediPharm Labs, each ml contains 50mg CBD and 2mg THC.
Study: NCT05754840
Drug: MPL-005
Normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD. The MPL-005 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 5mg THC.
Study: NCT05754840
Drug: MPL-009
Normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD. The MPL-009 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 25mg THC.
Study: NCT05679024
Drug: Apixaban 2.5 milligram Oral Tablet
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Tablet
Study: NCT05013463
Drug: Hydroxychloroquine Pill
Normalized name: hydroxychloroquine Pill
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Hydroxychloroquine, 200mg BID
Study: NCT04596475
Drug: glecaprevir/pibrentasvir (GLE/PIB)
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.
Study: NCT05974280
Drug: Alofisel
DrugBank: Darvadstrocel (DB16581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alofisel is made up of 'mesenchymal stem cells' from the fat tissue of a donor. Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease
Study: NCT05974280
Drug: Fat stem cell
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesenchymal stem cells from adipose (fat) tissue injection
Study: NCT05827991
Drug: 5% minoxidil external use
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
Study: NCT05952544
Drug: essential amino acids and keto-analogues supplementation
Normalized name: Keto-C
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: very low protein diet plus essential amino acids and keto-analogues supplementation
Study: NCT04882163
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220
Study: NCT04882163
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin
Study: NCT04882163
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab
Study: NCT04882163
Drug: Tafasitamab
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tafasitamab
Study: NCT04882163
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine
Study: NCT04882163
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin
Study: NCT04882163
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone
Study: NCT04882163
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine
Study: NCT04882163
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide
Study: NCT06167694
Drug: HRS-8080; Dalpiciclib Isethionate Tablets
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-8080 combined with Dalpiciclib Isethionate Tablets
Study: NCT05547737
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross - line treatment of Camrelizumab in non-small cell lung cancer
Study: NCT05392686
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirelizumab
Study: NCT05392686
Drug: PARP inhibitor
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzopari capsule
Study: NCT04622007
Drug: Tomivosertib
Normalized name: Tomivosertib
DrugBank: Tomivosertib (DB15219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals
Study: NCT04622007
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
Study: NCT06385600
Drug: Labetalol
Normalized name: Labetalol
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.
Study: NCT06385600
Drug: Phentolamine
Normalized name: Phentolamine
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
Study: NCT05363280
Drug: AL8326 low dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken AL3826 at low dose orally
Study: NCT04834440
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all patients will receive femoral nerve block using same volume of ropivacaine but in different concentrations
Study: NCT05363280
Drug: AL8326 high dose group
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken AL3826 at high dose orally
Study: NCT00000640
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000640
Drug: Sulfamethoxazole-Trimethoprim
Normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000640
Drug: Dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05351892
Drug: Elinzanetant (BAY3427080)
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gel capsule, oral
Study: NCT00176020
Drug: nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04543682
Drug: 0.125 ng/kg/min Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours
Study: NCT04543682
Drug: 0.25 ng/kg/min Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours
Study: NCT06520163
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1\~Day 2: 75mg/m\^2
Study: NCT06520163
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1\~Day 2: 200g/m\^2, q12h
Study: NCT05070221
Drug: Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)
Normalized name: Recombinant human interleukin-2
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: less than 8mL/time，Q2W，i.t.；
Study: NCT05070221
Drug: Recombinant humanized anti-PD-1 monoclonal antibody for injection
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg/time，Q3W，i.v.；
Study: NCT05070221
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg，bid，p.o.；
Study: NCT05006469
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, \>70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
Study: NCT06520163
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Study: NCT00001133
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001133
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05505747
Drug: Fisetin
Normalized name: FISETIN
DrugBank: Fisetin (DB07795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
Study: NCT05997641
Drug: DF-003
Normalized name: DF-1001
DrugBank: DF-1001 (DB18231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration by capsules (1 mg, 5 mg, or 25 mg).
Study: NCT05382715
Drug: Ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT06520163
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: From Day 6, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Study: NCT00299208
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00299208
Drug: Quinine
Normalized name: Quinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05182151
Drug: Istradefylline 40 mg
Normalized name: istradefylline 40 MG
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: adenosine A2A receptor antagonist
Study: NCT05801835
Drug: (cytarabine: daunorubicin) liposome for injection
Normalized name: cytarabine liposome / daunorubicin liposomal Injection
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
Study: NCT05801835
Drug: Vyxeos
Normalized name: Vyxeos
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
Study: NCT05801835
Drug: (cytarabine: daunorubicin) liposome for injection
Normalized name: cytarabine liposome / daunorubicin liposomal Injection
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
Study: NCT05801835
Drug: Vyxeos
Normalized name: Vyxeos
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
Study: NCT05028608
Drug: Elinzanetant (BAY3427080)
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elinzanetant given orally as a single dose in Period 1 and in Period 2.
Study: NCT05028608
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam given orally as single dose in Period 1 and in Period 2.
Study: NCT05028608
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine given orally twice daily in Period 2 .
Study: NCT04353180
Drug: Isotretinoin (13 cis retinoic acid ) capsules
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days